Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2379 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2010  |  Volume : 21  |  Issue : 1  |  Page : 43-49
Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis

Prince Salman Center for Kidney Disease, Riyadh, Saudi Arabia

Correspondence Address:
Khalid A Al-Saran
Prince Salman Center for Kidney Disease, Riyadh
Saudi Arabia
Login to access the Email id

PMID: 20061691

Rights and Permissions

Low-molecular-weight heparin (LMWH) has been suggested as providing safe, effi­cient, convenient, and possibly more cost-effective anticoagulation for hemodialysis (HD) than un­fractionated heparin (UFH) with a single bolus dose at the start of hemodialysis effectively pre­vents clot formation in the dialyzer and bubble trap with fewer side-effects and possible benefits on uremic dyslipidemia. In this study, we compared the safety, clinical efficacy, and cost effectiveness of Tinzaparin sodium (Innohep) with unfractionated heparin (UFH) in 23 chronic HD patients; their extracorporeal anticoagulant protocol-consisted of UFH was switched to Tinzaparin for a period of 6 months. Clinical clotting (grade 1-4) was evaluated by visual inspection after blood draining of the air trap every hour and the dialyzer after each session. Anticoagulation with Tinzaparin sodium re­sulted in less frequent dialyzer and air-trap clotting compared to UFH (P= 001 and 0.04 respec­tively). Over 24 weeks, we observed no alteration in the serum lipid profile of the patients. There was a statistically significant improvement in the dialysis single pool Kt/V after 6 months of Tinza­parin use (1.40 ± 0.28 for Tinzaparin versus 1.23 ± 0.28 for heparin) without any modification in the hemodialysis prescription. The total cost for 24 weeks use of Tinzaparin sodium was 23% more expensive compared to that for UFH. We conclude that a single bolus of Tinzaparin sodium injec­tion at the start of the dialysis session was more effective and convenient in our patients than UFH, but at a higher total cost. Furthermore, at least on the short term, there was no observed benefit on the lipid profile.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded933    
    Comments [Add]    
    Cited by others 1    

Recommend this journal